Leucadia National - BIO-TECHNE CORP ownership

BIO-TECHNE CORP's ticker is TECH and the CUSIP is 09073M104. A total of 536 filers reported holding BIO-TECHNE CORP in Q1 2023. The put-call ratio across all filers is 0.40 and the average weighting 0.2%.

About BIO-TECHNE CORP

Bio-Techne Corp is a leading provider of innovative life science research tools and diagnostic solutions. The company is headquartered in Minneapolis, Minnesota, and has operations in over 50 countries worldwide. Bio-Techne's products and services are used by researchers and clinicians in a wide range of fields, including cancer research, stem cell research, and immunology.

Bio-Techne's success is due in large part to its commitment to innovation and customer service. The company invests heavily in research and development, and has a team of over 1,000 scientists working to develop new products and technologies. Bio-Techne also has a strong focus on customer service, with a dedicated team of technical support specialists available to assist customers with any questions or issues they may have.

In addition to its research tools and diagnostic solutions, Bio-Techne also has a growing portfolio of clinical diagnostic products. The company's Exosome Diagnostics subsidiary is a leader in the development of liquid biopsy tests for cancer diagnosis and monitoring.

Bio-Techne's leadership team is comprised of experienced executives with a track record of success in the life sciences industry. Charles Kummeth, the company's CEO, has been with Bio-Techne since 2013 and has overseen significant growth and expansion during his tenure.

Overall, Bio-Techne is a company with a strong reputation for innovation, customer service, and leadership in the life sciences industry. With a growing portfolio of products and services, the company is well-positioned for continued success in the years to come.

It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.

Quarter-by-quarter ownership
Leucadia National ownership history of BIO-TECHNE CORP
ValueSharesWeighting
Q2 2023$1,748,270
+28.8%
21,417
+17.0%
0.02%
+45.5%
Q1 2023$1,357,677
+127.8%
18,300
+154.5%
0.01%
+175.0%
Q4 2022$595,907
-40.6%
7,190
+42.4%
0.00%
-96.0%
Q1 2019$1,003,000
-20.3%
5,050
-41.9%
0.10%
-32.4%
Q4 2018$1,259,000
-14.4%
8,699
+20.7%
0.15%
+23.3%
Q3 2018$1,471,000
+19.2%
7,206
-13.6%
0.12%
+26.3%
Q2 2018$1,234,000
-11.9%
8,342
-10.0%
0.10%
-4.0%
Q1 2018$1,400,000
+326.8%
9,270
+266.4%
0.10%
+296.0%
Q4 2017$328,000
-4.1%
2,530
-10.5%
0.02%
-13.8%
Q3 2017$342,0002,8270.03%
Other shareholders
BIO-TECHNE CORP shareholders Q1 2023
NameSharesValueWeighting ↓
Broadcrest Asset Management, LLC 300,000$24,489,00021.05%
Montanaro Asset Management Ltd 388,800$31,737,7445.02%
Sandhill Capital Partners LLC 502,447$41,014,7753.74%
Brown Capital Management 3,160,892$258,023,6143.66%
DF DENT & CO INC 3,275,617$267,388,6403.62%
Ownership Capital B.V. 2,282,104$186,288,1503.26%
Jackson Square Partners, LLC 1,361,789$111,162,8363.24%
STONE RUN CAPITAL, LLC 88,135$7,194,4603.20%
Pembroke Management, LTD 339,591$27,720,8132.99%
Summit Creek Advisors LLC 283,693$23,157,8602.90%
View complete list of BIO-TECHNE CORP shareholders